David Margolis, MD, MPH

Director of HIV Drug Development
ViiV Healthcare

Disclosure: GlaxoSmithKline (Individual(s) Involved: Self): Shareholder; ViiV Healthcare (Individual(s) Involved: Self): Employee

Presentation(s):

• 116 - Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study

  Oral Abstract

• LB-8 - Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials

  Saturday, October 24, 2020
  11:00am – 11:10am EDT